Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Patrick Gilligan

Orthopaedic Surgery Albuquerque, NM Medical Doctor

NPI 1043638802 CMS profile 1394792

500 Walter St Ne Ste 309, Albuquerque, NM 87102

Open in the dashboard

General payments

$5,903

63 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Gilligan of Albuquerque, NM is reported in the CMS Open Payments database as having received $5,903 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,640 19
2024 General $1,005 12
2023 General $657 9
2022 General $794 11
2021 General $127 2
2020 General $1,680 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Gilligan
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Patrick Gilligan were reported at $1,640. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Patrick Gilligan Orthopaedic Surgery median Middle half National median
2019 $0 $644 $140–$2,844 $163
2020 $1,680 $312 $75–$1,860 $114
2021 $127 $520 $117–$2,495 $132
2022 $794 $598 $128–$2,731 $149
2023 $657 $461 $128–$2,264 $160
2024 $1,005 $497 $134–$2,475 $164
2025 $1,640 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Stryker Corporation $3,107 37 payments
  2. Heraeus Medical, LLC. $1,417 2 payments
  3. Smith+Nephew, Inc. $524 10 payments
  4. Zimmer Biomet Holdings, Inc. $394 6 payments
  5. Becton, Dickinson and Company $202 2 payments
  6. Davol Inc. $144 1 payment
  7. Vertex Pharmaceuticals Incorporated $34 1 payment
  8. Bioventus LLC $26 1 payment
  9. Medline Industries, Inc. $26 1 payment
  10. Medtronic, Inc. $17 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,794 58 payments
  2. Travel and Lodging $2,097 4 payments
  3. Consulting Fee $12 1 payment
Products named General payments · program years 2020–2025
  1. MAKO $2,715 27 payments
  2. PALACOS $1,417 2 payments
  3. TRIATHLON $544 10 payments
  4. EVOS $234 2 payments
  5. ARISTA AH FlexiTip Surgery $202 2 payments
  6. mymobility Platform $177 2 payments
  7. ARISTA AH FLEXITIP BD Interventional Surgery $144 1 payment
  8. TRIGEN InterTAN $107 1 payment
  9. ACCOLADE $103 3 payments
  10. Affixus $94 1 payment
  11. Other $1,029 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

531

Median for Orthopedic Surgery: 203

Drug cost

$4,184

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mupirocin Generic 176 $1,387
Naloxone Hcl Generic 18 $1,118
Oxycodone Hcl Generic 78 $476
Cefadroxil Generic 16 $284
Ondansetron Hcl Generic 27 $182
Celecoxib Generic 24 $179
Gabapentin Generic 26 $143
Meloxicam Generic 38 $101
Tramadol Hcl Generic 21 $93
Cephalexin Generic 29 $91

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$175,781

Of which drugs: $2,008

Medicare patients

282

Average age 73

Services billed

1,444

172 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Chronic kidney disease 27%
Ischemic heart disease 25%
Depression 23%
Osteoporosis 22%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 200 $148

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record